Navigation Links
CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
Date:11/3/2008

- Data presented at the 2008 iSBTc Annual Meeting -

- Conference call to be hosted today at 11:00 a.m. ET to discuss results -

BRANFORD, Conn., Nov. 3 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN) announced today preliminary data from an ongoing Phase II trial of CR011-vcMMAE, an antibody-drug conjugate that targets GPNMB, for the treatment of patients with unresectable Stage III or Stage IV melanoma. Dr. Patrick Hwu, Co-Principal Investigator, and Professor and Chairman of the Department of Melanoma Medical Oncology, at The University of Texas M. D. Anderson Cancer Center, presented the data during an oral session at the 2008 International Society for Biologic Therapy of Cancer (iSBTc) Annual Meeting.

Thirty-six patients were enrolled into this Phase II open-label, multi-center trial that is evaluating the efficacy and safety of CR011-vcMMAE 1.88 mg/kg administered intravenously once every three weeks. Eligible patients had progressive disease at trial entry and may have received one prior cytotoxic regimen and any number of prior immunotherapies. Of the patients enrolled, 94% had Stage IV disease of which two-thirds were classified as M1c, the poorest risk group.

At the time of the data cutoff for this analysis (19 Sept 2008), 31 patients had at least one efficacy assessment available, and 18 patients were continuing to receive ongoing treatment in the study. The median overall progression-free survival (PFS) to date was approximately 4.5 months. RECIST-defined partial responses were reported in 3 patients, 2 ongoing, and an unconfirmed partial response in 1 patient. Nineteen patients had stable disease, 14 ongoing, with tumor shrinkage observed in 12 of these patients.

"PFS is a cli
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
11. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 Research and Markets ... Cancer Market 2014-2018" report to their offering. ... growth of cancerous cells in the breast tissue. It ... cancer is rare. Histologically, breast cancer can be classified ... undifferentiated carcinoma. Ductal carcinoma is the form of breast ...
(Date:9/16/2014)... , 17. September 2014 ... ), hat heute die Markteinführung des ... Probenverarbeitung, in Europa bekannt gegeben. Der ... Universalplattform zur Vereinfachung der präanalytischen Probenverarbeitung. ... und fehlerbehaftete Arbeitsschritte bei der manuellen ...
(Date:9/16/2014)... 2014 3SBio Inc., ("3SBio") a leading ... focusing on researching, developing, manufacturing and marketing ... into an exclusive license agreement with JenKem Technology ... marketing in Mainland China of PEG-irinotecan, a long-acting ... is over-expressed in many solid tumors, including colorectal, ...
Breaking Medicine Technology:Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis 2Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis 3Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 2Hologic stellt in Europa den Tomcat vor, ein neues Gerät zur präanalytischen Probenverarbeitung 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 23SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 43SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 5
... N.J., Oct. 27 Watson Pharmaceuticals, Inc. (NYSE: ... Laboratories, Inc., filed a new drug application under Section ... (FFDCA) with the U.S. Food and Drug Administration (FDA) ... and 40 mg tablets.  Watson,s rosuvastatin zinc tablets are ...
... Oct. 27 Intrinsic Bioprobes today announced that ... issued US Patent 7,816,095 covering novel blood protein ... first of a series of patent applications that ... clinical utility. "The biomarkers were discovered ...
Cached Medicine Technology:Watson Confirms Crestor® Patent Challenge 2Intrinsic Bioprobes Announces Issuance of US Patent for Novel Biomarkers and Assays for Myocardial Infarction 2
(Date:9/17/2014)... With the development of China’s economy, ... human body physiology, preventing diseases, promoting health, prolonging ... variety of specific populations. In 2013, the market ... billion, up 12.0% year on year, recording a ... product industry is composed of many extremely scattered ...
(Date:9/17/2014)... 2014 U.S. News and World ... country, and three mesothelioma treatment centers made the ... mesothelioma law firm Baron and Budd ... of Texas MD Anderson Cancer Center and Brigham ... ( http://health.usnews.com/best-hospitals/rankings/cancer ) , U.S. News and World ...
(Date:9/17/2014)... DMG Productions announces the upcoming airing ... broadcast on Wednesday, September 24, 2014 at 7:30 ... episode, Innovations will go behind the scenes to ... each client the opportunity to achieve the highest ... principles of Care, Compassion, and Commitment. , Audiences ...
(Date:9/17/2014)... 17, 2014 Experienced dress company, Discount-Dress.com, ... new selection of trendy black bridesmaid dresses. Furthermore, the ... its beautiful bridesmaid outfits. Readers can view more ... Discount-Dress.com is a famous brand of special ... additions as well as revamped old editions, the supplier ...
(Date:9/17/2014)... 17, 2014 Headquartered in Baltimore, Maryland, ... reach across the country. , “The past two ... “We have grown to over 400 evaluators in 46 ... evaluators in the Midwest and South Dakota and Vermont. ... facilities where our volunteers can visit.” , TPU provides ...
Breaking Medicine News(10 mins):Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 2Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 3Health News:China Health Food Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com 4Health News:Three Mesothelioma Treatment Centers Make U.S. News and World Report’s List of Top Cancer Care Facilities, Baron and Budd Reports 2Health News:Three Mesothelioma Treatment Centers Make U.S. News and World Report’s List of Top Cancer Care Facilities, Baron and Budd Reports 3Health News:Innovations to Explore Substance Abuse and Mental Health in Upcoming Episode Airing Wednesday, September 24, 2014 via Discovery Channel. 2Health News:Discount-Dress.com’s Top Designers Are Now Busy Making Its New Black Bridesmaid Dresses 2Health News:Therapy Pets Unlimited is Expanding 2Health News:Therapy Pets Unlimited is Expanding 3
... An alert over potential outbreak of 'Legionnaires Disease' has ... visited the Grand Atlantic Hotel before 10 Nov in ... samples tested positive for Legionelle Bacteria. The hotel which ... out a thorough disinfection. ,The Legionnaires disease ...
... OF HIGH BLOOD PRESSURE DOES NOT PREDICT EFFECT ON HEART ... blood pressure can lead to a potentially dangerous enlargement of ... at the Johns Hopkins Children's Center and the Children's Hospital ... not true for children, at least, that the higher the ...
... Britain has revealed that almost 59,000 Brits have an HIV ... cases were diagnosed last year. //,70 per cent of the ... Eastern Europe. Bulgaria and Romania are among the nations with ... ,It has been found that almost none of ...
... contributed to the health ratings of the famous spirit, known ... in much the same way as mice on a normal ... conducted by Harvard Scientists. ,Delving more into the ... blessings, following a second study conducted on mice. The compound ...
... fight the stigma of the disease. // ,According to ... fallen to 1.56 percent in 2005, from 14.7 percent in 2001. ... the cured are called, have been roped in since leprosy is ... in Ranchi has gone up to 1.60 percent between April and ...
... revelation, some researchers have discerned a thread of similarity ... likeness of character. //For instance, it was observed that ... had a past criminal record compared to owners of ... ,During a study of 355 dog owners in Ohio, ...
Cached Medicine News:Health News:Children and Chronic Kidney Disease 2Health News:Children and Chronic Kidney Disease 3
... developed the world's first 8-channel ... completely AC powered in 1951. ... a number of standard setting ... systems, such as a Windows ...
... you're getting an ambulatory and a clinical EEG ... Mobee O2 can be used for ambulatory EEG ... or in-lab sleep studies. And both feature 32 ... placement. The Mobee O2 includes the additional enhancement ...
... The VISULAS 690s is the ... the instrument of choice for ... clinical trials, Carl Zeiss has ... in laser manufacturing to create ...
... Humphrey Lens Analyzers Model 350 and ... most comprehensive lensometry for your practice. ... Analyzer (LA) gives fast and accurate ... lenses, prism lenses, contact lenses, polycarbonate ...
Medicine Products: